中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(11): 2742-2744

Research advances in surgical margin of hilar cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2021.11.056

  • Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Research funding:

Project of Standardized Diagnosis and Treatment of Key Diseases in Jiangsu Province (BE2016789);

National Natural Science Foundation of China (81670570)

  • Received Date: 2021-04-01
  • Accepted Date: 2021-04-16
  • Published Date: 2021-11-20
    Abstract
  • Hilar cholangiocarcinoma (HCCA) is the most common biliary malignancy, and surgical operation is the only possible treatment method at present. The nature of surgical margin is an important influencing factor for the long-term survival of patients, and radical resection can bring great survival benefits to patients. The determination of radial margin for HCCA can help to evaluate the nature of surgical margin and predict the prognosis of patients more accurately. This article reviews the latest research advances in the surgical margin of HCCA.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    RIZVI S, KHAN SA, HALLEMEIER CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111. DOI: 10.1038/nrclinonc.2017.157.
    [2]
    SAHA SK, ZHU AX, FUCHS CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S. : Intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5): 594-599. DOI: 10.1634/theoncologist.2015-0446.
    [3]
    BANALES JM, MARIN J, LAMARCA A, et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(9): 557-588. DOI: 10.1038/s41575-020-0310-z.
    [4]
    KHAN AS, DAGEFORDE LA. Cholangiocarcinoma[J]. Surg Clin North Am, 2019, 99(2): 315-335. DOI: 10.1016/j.suc.2018.12.004.
    [5]
    LI XC, FENG QC. Advance and controversy of hilar cholangiocarcinoma[J]. J Clin Hepatol, 2019, 35(12): 2632-2637. DOI: 10.3969/j.issn.1001-5256.2019.12.004.

    李相成, 冯勤超. 肝门部胆管癌的进展与争议[J]. 临床肝胆病杂志, 2019, 35(12): 2632-2637. DOI: 10.3969/j.issn.1001-5256.2019.12.004.
    [6]
    FORNER A, VIDILI G, RENGO M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma[J]. Liver Int, 2019, 39(Suppl 1): 98-107. DOI: 10.1111/liv.14086.
    [7]
    SAKAMOTO Y, KOSUGE T, SHIMADA K, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: An analysis of 55 patients concerning the significance of ductal and radial margins[J]. Surgery, 2005, 137(4): 396-402. DOI: 10.1016/j.surg.2004.10.008.
    [8]
    MANTEL HT, WESTERKAMP AC, SIEDERS E, et al. Intraoperative frozen section analysis of the proximal bile ducts in hilar cholangiocarcinoma is of limited value[J]. Cancer Med, 2016, 5(7): 1373-1380. DOI: 10.1002/cam4.693.
    [9]
    SHINOHARA K, EBATA T, SHIMOYAMA Y, et al. A study on radial margin status in resected perihilar cholangiocarcinoma[J]. Ann Surg, 2021, 273(3): 572-578. DOI: 10.1097/SLA.0000000000003305.
    [10]
    STREMITZER S, STIFT J, LAENGLE J, et al. Prognosis and circumferential margin in patients with resected hilar cholangiocarcinoma[J]. Ann Surg Oncol, 2021, 28(3): 1493-1498. DOI: 10.1245/s10434-020-09105-1.
    [11]
    AHMAD J, LOUGHREY MB, DONNELLY D, et al. Prognostic value of added stratification of circumferential resection margin status in oesophageal carcinoma[J]. Histopathology, 2013, 62(5): 752-763. DOI: 10.1111/his.12078.
    [12]
    BUETTNER S, MARGONIS GA, KIM Y, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma[J]. HPB (Oxford), 2016, 18(6): 510-517. DOI: 10.1016/j.hpb.2016.04.001.
    [13]
    RIBERO D, PINNA AD, GUGLIELMI A, et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis of 434 patients[J]. Arch Surg, 2012, 147(12): 1107-1113. DOI: 10.1001/archsurg.2012.1962.
    [14]
    de JONG MC, MARQUES H, CLARY BM, et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: A multi-institutional analysis of 305 cases[J]. Cancer, 2012, 118(19): 4737-4747. DOI: 10.1002/cncr.27492.
    [15]
    SHINGU Y, EBATA T, NISHIO H, et al. Clinical value of additional resection of a margin-positive proximal bile duct in hilar cholangiocarcinoma[J]. Surgery, 2010, 147(1): 49-56. DOI: 10.1016/j.surg.2009.06.030.
    [16]
    LI CX, ZHANG H, WANG K, et al. Preoperative bilirubin level predicts overall survival and tumor recurrence after resection for perihilar cholangiocarcinoma patients[J]. Cancer Manag Res, 2019, 11: 10157-10165. DOI: 10.2147/CMAR.S230620.
    [17]
    KOMAYA K, EBATA T, YOKOYAMA Y, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: Analysis of a large cohort with a close postoperative follow-up approach[J]. Surgery, 2018, 163(4): 732-738. DOI: 10.1016/j.surg.2017.08.011.
    [18]
    ZHANG XF, SQUIRES MH 3rd, BAGANTE F, et al. The impact of intraoperative re-resection of a positive bile duct margin on clinical outcomes for hilar cholangiocarcinoma[J]. Ann Surg Oncol, 2018, 25(5): 1140-1149. DOI: 10.1245/s10434-018-6382-0.
    [19]
    OGURO S, ESAKI M, KISHI Y, et al. Optimal indications for additional resection of the invasive cancer-positive proximal bile duct margin in cases of advanced perihilar cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(6): 1915-1924. DOI: 10.1245/s10434-014-4232-2.
    [20]
    GOVIL S, REDDY MS, RELA M. Surgical resection techniques for locally advanced hilar cholangiocarcinoma[J]. Langenbecks Arch Surg, 2014, 399(6): 707-716. DOI: 10.1007/s00423-014-1216-4.
    [21]
    PORUK KE, PAWLIK TM, WEISS MJ. Perioperative management of hilar cholangiocarcinoma[J]. J Gastrointest Surg, 2015, 19(10): 1889-1899. DOI: 10.1007/s11605-015-2854-8.
    [22]
    SOARES KC, KAMEL I, COSGROVE DP, et al. Hilar cholangiocarcinoma: Diagnosis, treatment options, and management[J]. Hepatobiliary Surg Nutr, 2014, 3(1): 18-34. DOI: 10.3978/j.issn.2304-3881.2014.02.05.
    [23]
    WEISS MJ, COSGROVE D, HERMAN JM, et al. Multimodal treatment strategies for advanced hilar cholangiocarcinoma[J]. Langenbecks Arch Surg, 2014, 399(6): 679-692. DOI: 10.1007/s00423-014-1219-1.
    [24]
    CHATELAIN D, FARGES O, FUKS D, et al. Assessment of pathology reports on hilar cholangiocarcinoma: The results of a nationwide, multicenter survey performed by the AFC-HC-2009 study group[J]. J Hepatol, 2012, 56(5): 1121-1128. DOI: 10.1016/j.jhep.2011.12.010.
    [25]
    MIYAZAKI M, KIMURA F, SHIMIZU H, et al. Extensive hilar bile duct resection using a transhepatic approach for patients with hepatic hilar bile duct diseases[J]. Am J Surg, 2008, 196(1): 125-129. DOI: 10.1016/j.amjsurg.2007.04.020.
    [26]
    XIONG J, NUNES QM, HUANG W, et al. Major hepatectomy in Bismuth types I and Ⅱ hilar cholangiocarcinoma[J]. J Surg Res, 2015, 194(1): 194-201. DOI: 10.1016/j.jss.2014.10.029.
    [27]
    CHEN YJ, ZHOU R. Application of mesohepatectomy with caudate lobectomy in hilar cholangiocarcinoma[J]. Chin J Dig Surg, 2021, 20(1): 52-58. DOI: 10.3760/cma.j.cn115610-20201116-00727.

    陈亚进, 周睿. 中肝叶联合尾状叶切除术在肝门部胆管癌中的应用[J]. 中华消化外科杂志, 2021, 20(1) : 52-58. DOI: 10.3760/cma.j.cn115610-20201116-00727.
    [28]
    IKEYAMA T, NAGINO M, ODA K, et al. Surgical approach to Bismuth type I and Ⅱ hilar cholangiocarcinomas: Audit of 54 consecutive cases[J]. Ann Surg, 2007, 246(6): 1052-1057. DOI: 10.1097/SLA.0b013e318142d97e.
    [29]
    WANG H, YAO XX, QIAO SX. Controversies over the extent of surgical resection for hilar cholangiocarcinoma and research advances in diagnosis and treatment[J]. J Clin Hepatol, 2020, 36(3): 704-707. DOI: 10.3969/j.issn.1001-5256.2020.03.053.

    汪宏, 姚小晓, 乔士兴. 肝门部胆管癌手术切除范围的争议及诊疗进展[J]. 临床肝胆病杂志, 2020, 36(3): 704-707. DOI: 10.3969/j.issn.1001-5256.2020.03.053.
    [30]
    NIMURA Y, HAYAKAWA N, KAMIYA J, et al. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus[J]. World J Surg, 1990, 14(4): 535-543; discussion 544. DOI: 10.1007/BF01658686.
    [31]
    MANSOUR JC, ALOIA TA, CRANE CH, et al. Hilar cholangiocarcinoma: Expert consensus statement[J]. HPB (Oxford), 2015, 17(8): 691-699. DOI: 10.1111/hpb.12450.
    [32]
    KIM SJ, KIM MJ, HAN JS, et al. Prediction of recurrence with KRAS mutational burden using ultrasensitive digital polymerase chain reaction of radial resection margin of resected pancreatic ductal adenocarcinoma[J]. Pancreas, 2019, 48(3): 400-411. DOI: 10.1097/MPA.0000000000001255.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (591) PDF downloads(41) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return